Myasthenia gravis (MG) is an autoimmune disease caused mainly by antibodies against skeletal muscle nicotinic acetylcholine receptors (nAChRs) at the postsynaptic membrane resulting in depletion of acetylcholine at the neuromuscular junction (NMJ). Muscle fatigue is the cardinal symptom of MG. Respiratory muscle weakness and breathing problems are manifestations of MG even in mild stages of the disease resulting in significant morbidity and mortality. Also sleep related conditions are among the manifestations of MG which include sleep disordered breathing (SDB) [i.e. central (CSA) and obstructive (OSA) sleep apneas, hypoventilation or hypoxemic syndromes], reduced sleep efficiency and quality, increased number of nocturnal awakenings, excessive daytime sleepiness, reduced rapid eye movement sleep and altered sleep perception and dreaming. On the other hand, sleep abnormalities may result in lack of concentration, cognitive impairments and mood disturbances as depression and anxiety. Central and peripheral mechanisms have been suggested for the association between MG and central nervous system manifestations and sleep abnormalities. Neurologists and sleep medicine professionals should be aware of the associations between OSA/CSA, hypoventilation and other sleep related conditions with MG and consider systematic investigations including polysomnography and ventilatory support. This will reduce morbidity and mortality and improve quality of lives of patients with MG.
| Published in |
Science Journal of Public Health (Volume 4, Issue 2-1)
This article belongs to the Special Issue Obstructive Sleep Apnea: A Systemic Disease |
| DOI | 10.11648/j.sjph.s.2016040201.12 |
| Page(s) | 6-16 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2015. Published by Science Publishing Group |
Myasthenia Gravis, Neuromuscular Diseases, Sleep Disordered Breathing, Obstructive Sleep Apnea, Central Sleep Apnea, Hypoventilation
| [1] | Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Neurology. 1976;26(11):1054–9. |
| [2] | Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797–810. |
| [3] | Ferguson IT, Murphy RP, Lascelles RG. Ventilatory failure in myasthenia gravis. J Neurol Neurosurg Psychiatry. 45(3):217-22. |
| [4] | Marlowe FI, D’Angelo AJ Jr. Respiratory failure as the initial presentation of myasthenia gravis. Ear Nose Throat J. 1989;68(6):472-3. |
| [5] | Shintani S, Shiozawa Z, Shindo K, Matsui T, Tsunoda S. Sleep apnea in well-controlled myasthenia gravis. Rinsho Shinkeigaku. 1989;29(5):547-53. |
| [6] | Quera-Salva MA, Guilleminault C, Chevret S, Troche G, Fromageot C, Crowe McCann C, Stoos R, de Lattre J, Raphael JC, Gajdos P. Breathing disorders during sleep in myasthenia gravis. Ann Neurol. 1992;31(1):86–92. |
| [7] | Stepansky R, Weber G, Zeitlhofer J. Sleep apnea in myasthenia gravis. Wien Med Wochenschr. 1996;146(9-10):209-10. |
| [8] | Amino A, Shiozawa Z, Nagasaka T, Shindo K, Ohashi K, Tsunoda S, Shintani S. Sleep apnoea in well-controlled myasthenia gravis and the effect of thymectomy. J Neurol. 1998;22(2):77-80. |
| [9] | Nicolle MW, Rask S, Koopman WJ, George CF, Adams J, Wiebe S. Sleep apnea in patients with myasthenia gravis. Neurology. 2006;67(1):140-2. |
| [10] | Morgenstern M, Singas E, Zleik B, Greenberg H. Resolution of severe obstructive sleep apnea after treatment of anti-muscle kinase receptor-positive myasthenia gravis despite 60-pound weight gain. J Clin Sleep Med. 2014;10(7):813-4. |
| [11] | Happe S, Klösch G, Zeitlhofer J. Perception of dreams and subjective sleep quality in patients with myasthenia gravis. Neuropsychobiology. 2004;50(1):21-7. |
| [12] | Prudlo J, Koenig J, Ermert S, Juhász J. Sleep disordered breathing in medically stable patients with myasthenia gravis. Eur J Neurol. 2007;14(3):321-6. |
| [13] | Martínez-Lapiscina EH, Erro ME, Ayuso T, Jericó I. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve. 2012;46(2):174-80. |
| [14] | Sieminski M, Bilińska M, Nyka WM. Increased frequency of restless legs syndrome in myasthenia gravis. Eur Neurol. 2012;68(3):166-70. |
| [15] | Tucker DM, Roeltgen DP, Wann PD, Wertheimer RI. Memory dysfunction in myasthenia gravis: Evidence for central cholinergic effects. Neurology. 1988;38(3):1173–7. |
| [16] | Riker WF. Memory impairment in myasthenia gravis. Neurology. 1989;39(4):611-2. |
| [17] | Glennerster A, Palace J, Warburton D, Oxbury S, Newsom-Davis J. Memory in myasthenia gravis: neuropsychological tests of central cholinergic function before and after effective immunologic treatment. Neurology. 1996;46(4):1138-42. |
| [18] | Hamed SA, Youssef AH, Abd ElHameed MA, Mohamed MF, Elattar AM. Assessment of cognitive function in patients with myasthenia gravis. Neuroimmunology Neuroinflammation. 2014:1(3):141-146. |
| [19] | Vernino S, Cheshire WP, Lennon VA. Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci. 2001;88(3):187-92. |
| [20] | Hamed SA, Mohamed KO, Mohamad MMA. Cardiac autonomic function in Patients with Myasthenia Gravis. Neuroimmunol Neuroinflammation. 2015:2(1):33-7. |
| [21] | Hamed SA, Elattar AM, Hamed EA. Irreversible Cochlear Damage in Myasthenia Gravis: Otoacoustic emissions analysis. Acta Neurol Scand. 2006;113(1):46-54. |
| [22] | Magni G, Micaglio GF, Lalli R, Bejato L, Candeago MR, Merskey H, Angelini C. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand. 1988;77(4):443–5. |
| [23] | Tabbaa MA, Leshner RT, Campbell WW. Malignant thymoma with dysautonomia and disordered neuromuscular transmission. Arch Neuro.l 1986;43(9):955-7. |
| [24] | Lindstrom JM. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Ann N Y Acad Sci. 2003;998:41-52. |
| [25] | Lewis SW, Ron MA, Newsom-Davis J. Absence of central functional cholinergic deficits in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1989;52(2):258–61. |
| [26] | Paul RH, Cohen RA, Zawacki T, Gilchrist JM, Aloia MS. What have we learned about cognition in myasthenia gravis?: a review of methods and results. Neurosci Biobehav Rev. 2001;25(1):75-81. |
| [27] | Kurtzke JK, Kurland LT. Epidemiology of neurologic diseases; in baker AB, Baker LH (eds): Clinical Neurology. Philadelphia, Harper and Row 1982;47-49. |
| [28] | Phillips LH 2nd. The epidemiology of myasthenia gravis. Neurol Clin. 1994;12(2):263-71. |
| [29] | Osserman KE,ed. Myasthenia gravis. New York: Grune and Stratton 1958; 80. |
| [30] | Boruchoff SA, Goldberg B. Edrophonium (tensilon) in diagnosis of ocular myasthenia gravis. AMA Arch Ophthalmol. 1955;53(5):718-719. |
| [31] | Kearsey C, Fernando P, D'Costa D, Ferdinand P. The use of the ice pack test in myasthenia gravis. JRSM Short Rep. 2010;1(1):14. |
| [32] | Howard JF Jr, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert Eaton myasthenic syndrome. Neurol Clin. 1994;12(2):305-30. |
| [33] | Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365–8. |
| [34] | Pasnoor M, Wolfe GI, Nations S, Trivedi J, Barohn RJ, Herbelin L, McVey A, Dimachkie M, Kissel J, Walsh R, Amato A, Mozaffar T, Hungs M, Chui L, Goldstein J, Novella S, Burns T, Phillips L, Claussen G, Young A, Bertorini T, Oh S. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010;41(3):370-4. |
| [35] | Onodera H. The role of the thymus in the pathogenesis of myasthenia gravis. Tohoku J Exp Med. 2005;207(2):87-98. |
| [36] | Scheife RT, Hills JR, Munsat TL. Myasthenia gravis: signs, symptoms, diagnosis, immunology, and current therapy. Pharmacotherapy. 1981;1(1):39-54. |
| [37] | Chiu HC, Chen WH, Yeh JH. The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher. 2000;4(4):291-5. |
| [38] | Wegner B, Ahmed I. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin Neurol Neurosurg. 2002;105(1):3-8. |
| [39] | Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(1):7-15. |
| [40] | Kay A, Trinder J, Kim Y. Progressive changes in airway resistance during sleep. J Appl Physiol. 1996;81(1):282–96. |
| [41] | Morrell MJ, Harty HR, Adams L, Guz A. Breathing during wakefulness and NREM sleep in humans without an upper airway. J Appl Physiol. 1996;81(1):274–81. |
| [42] | Gould GA, Gugger M, Molloy J, Tsara V, Shapiro CM, Douglas NJ. Breathing pattern and eye movement density during REM sleep in humans. Am Rev Respir Dis. 1988;138(4):874-7. |
| [43] | Schmidt-Nowara WW, Marder EJ, Feil PA.: Respiratory failure in myasthenia gravis due to vocal cord paresis. Arch Neurol. 1984;41(5):567-8. |
| [44] | Mier-Jedrzejowicz AK, Brophy C, Green M. Respiratory muscle function in myasthenia gravis. Am Rev Respir Dis. 1988;138(4):867-73. |
| [45] | Spinelli A, Marconi G, Gorini M, Pizzi A, Scano G. Control of breathing in patients with myasthenia gravis. Am Rev Respir Dis. 1992;145(6):1359-66. |
| [46] | Yeh JH, Chen WH, Chiu HC, Lee CT, Hsu CY. Plasmapheresis does not affect polysomnographic parameters in patients with myasthenia gravis: a case series study. Artif Organs. 2010;34(6):E200-3. |
| [47] | Eckert DJ, Jordan AS, Merchia P, Malhotra A. Central sleep apnea: pathophysiology and treatment. Chest. 2007;131(2):595-607. |
| [48] | Malhotra A, White DP. Obstructive sleep apnoea. Lancet 2002;360(9328):237-45. |
| [49] | Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Rein J, Vela-Bueno A, Kales A. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med. 2001;163(3 Pt 1):608-13. |
| [50] | Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med. 1998;157(1):144–8. |
| [51] | Manni R, Piccolo G, Sartori I, Castelnovo G, Raiola E, Lombardi M, Cerveri I, Fanfulla F, Tartara A. Breathing during sleep in myasthenia gravis. Ital J Neurol Sci. 1995;16(9):589-94 |
| [52] | Papazian O. Rapid eye movement sleep alterations in myasthenia gravis. Neurology. 1976;26(4):311–6. |
| [53] | Sonka K, Klinderová J, Kolejáková M, Simková L, Nevsímalová S. MESAM4 evaluated nocturnal respiration disturbances in myasthenia gravis. Sb Lek. 1996;97(1):97-102. |
| [54] | Gajdos P, Quera Salva MA. Respiratory disorders during sleep and myasthenia. Rev Neurol (Paris). 2001;157(11 Pt 2):S145-7. |
| [55] | Hamed SA. Comorbid nervous system manifestations and disorders with myasthenia gravis: Evidences and possible mechanisms. J Neurol Neurosci. 2012;3(1):2. |
| [56] | Darnell RB. Paraneoplastic neurological disorders: windows into neuronal function and tumor immunity. Arch Neurol. 2004;61(1):30–2. |
| [57] | Mennuni G, Morante MT, Di Meo L, Scoppetta C, Strusi L, Neri G, Laudisio A, Mazza S, Bergonzi P. Myasthenia and sleep. Schweiz Arch Neurol Neurochir Psychiatr. 1983;133(2):193-203. |
| [58] | Kryger M, Roth T, Dement W. Principles and practice of sleep medicine (3rd ed.). Philadelphia: Saunders. 2000. |
| [59] | Lefvert AK, Pirskanen R. Acetylcholine-receptor antibodies in cerebrospinal fluid of patients with myasthenia gravis. Lancet. 1977;2(8033):351–2. |
| [60] | Adornato BT, Houff SA, Engel WK, Dalakas M, Madden DL, Sever JL. Abnormal immunoglobulin bands in cerebrospinal fluid in myasthenia gravis. Lancet. 1978;2(8085):367–8. |
| [61] | Keesey JC, Tourtellotte WW, Herrmann C, Andrews JM, Lindstrom J. Acetylcholine-receptor antibody in cerebrospinal fluid. Lancet. 1978;1(8067):777. |
| [62] | Kam-Hansen S. Asymptomatic oligoclonal CSF IgG and progressive increase of intrathecal IgG synthesis in a patient with myasthenia gravis treated with thymectomy – A 4-years follow-up. J Neurol Sci. 1986;75(3):285–92. |
| [63] | Tzartos SJ, Sophianos D, Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol. 1985;134(4):2343–9. |
| [64] | Salloum A, Rowley JA, Mateika JH, Chowdhuri S, Omran Q, Badr MS. Increased propensity for central apnea in patients with obstructive sleep apnea: effect of nasal continuous positive airway pressure. Am J Respir Crit Care Med. 2010;181(2):1891-3. |
| [65] | Qiu L, Feng HY, Huang X, Mo R, Ou CY, Luo CM, Li Y, Liu WB. Study of incidence and correlation factors of depression, anxiety and insomnia in patients with myasthenia gravis. Zhonghua Yi Xue Za Zhi. 2010;90(45):3176-9. |
| [66] | Paradis CM, Friedman S, Lazar RM, Kula RW. Anxiety disorders in a neuromuscular clinic. Am J Psychiatry. 1993;150(7):1102–4. |
| [67] | Ito S, Masuda M, Tanaka S, Takagi M, Tanaka C, Yamada N, Nakajima K, Akashi T, Hirano T, Utsumi H. Low-dose glucocorticoid therapy complements the pituitary-adrenocortical system and reduces anxiety and insomnia in myasthenia gravis patients. Clin Neuropharmacol. 2012;35(1):30-6. |
| [68] | Ji KH, Bae JS. CPAP therapy reverses weakness of myasthenia gravis: role of obstructive sleep apnea in paradoxical weakness of myasthenia gravis. J Clin Sleep Med. 2014;10(4):441-2. |
| [69] | Lange T, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci. 2010;1193:48–59. |
| [70] | Guilleminault C, Shergill RP. Sleep-disordered Breathing in Neuromuscular Disease. Curr Treat Options Neurol. 2002;4(2):107-12. |
| [71] | Bye PT, Ellis ER, Issa FG, Donnelly PM, Sullivan CE. Respiratory failure and sleep in neuromuscular disease. Thorax. 1990;45(4):241-7. |
| [72] | Baraka A. Anesthesia and myasthenia gravis. Can J Anaesth. 1992;39(5 Pt 1):476-86. |
| [73] | Kunst G, Graf BM, Schreiner R. Differential effects of sevoflurane, isoflurane, and halothane on Ca2+ release from the sarcoplasmic reticulum of skeletal muscle. Anesthesiology. 1999;91(1):179-86. |
| [74] | Clark M, Brunick A- Nitrous Oxide Interaction with the Body, em: Clark M, Brunick A - Nitrous Oxide and Oxygen Sedation. St. Louis, Mosby, 1999;103-14. |
| [75] | Saito Y, Sakura S, Takatori T, Kosaka Y. Epidural anesthesia in a patient with myasthenia gravis. Acta Anaesthesiol Scand. 1993;37(5):513-5. |
| [76] | Akpolat N, Tilgen H, Gürsoy F, Saydam S, Gürel A. Thoracic epidural anaesthesia and analgesia with bupivacaine for transsternal thymectomy for myasthenia gravis. Eur J Anaesthesiol. 1997;14(2):220-3. |
| [77] | Seifert HS, Smith DS. Neuroanesthesia and neurologic disease In: Longnecker DE, Murphy FL, Eds.; Introduction to Anesthesia. 9th ed. WB Saunders Co Philadelphia, PA: 1997, p. 400-414 |
| [78] | Dierdorf SF. Anesthesia for patients with rare and coexisting disease In: Barash PG, Cullen BF, Stoelting RK, Eds.; Clinical Anesthesia. 4th ed. Philadelphia, PA: 2001, p. 491-520 |
| [79] | Yeh JH, Lin CM, Chen WH, Chiu HC. Effects of double filtration plasmapheresis on nocturnal respiratory function in myasthenic patients. Artif Organs. 2013;37(12):1076-9. |
| [80] | Kassardjian CD, Murray BJ, Kokokyi S, Jewell D, Barnett C, Bril V, Katzberg HD. Effects of napping on neuromuscular fatigue in myasthenia gravis. Muscle Nerve. 2013;48(5):816-8. |
| [81] | Ellis ER, Bye PT, Bruderer JW, Sullivan CE. Treatment of respiratory failure during sleep in patients with neuromuscular disease. Positive-pressure ventilation through a nose mask. Am Rev Respir Dis. 1987;135(1):148-52. |
| [82] | Annane D, Orlikowski D, Chevret S. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev. 2014;12:CD001941. |
| [83] | Barbé F, Quera-Salva MA, de Lattre J, Gajdos P, Agustí AG. Long-term effects of nasal intermittent positive-pressure ventilation on pulmonary function and sleep architecture in patients with neuromuscular diseases. Chest. 1996;110(5):1179-83. |
| [84] | Piper AJ, Sullivan CE. Effects of long-term nocturnal nasal ventilation on spontaneous breathing during sleep in neuromuscular and chest wall disorders. Eur Respir J. 1996;9(7):1515-22. |
| [85] | Naseer S, Kolade VO, Idrees S, Naseer S, Chandra A. Improvement in ocular myasthenia gravis during CPAP therapy for sleep apnea. Tenn Med. 2012;105(9):33-4. |
APA Style
Sherifa Ahmed Hamed. (2015). Sleep Related Conditions with Myasthenia Gravis: Evidence, Causes and Implications. Science Journal of Public Health, 4(2-1), 6-16. https://doi.org/10.11648/j.sjph.s.2016040201.12
ACS Style
Sherifa Ahmed Hamed. Sleep Related Conditions with Myasthenia Gravis: Evidence, Causes and Implications. Sci. J. Public Health 2015, 4(2-1), 6-16. doi: 10.11648/j.sjph.s.2016040201.12
AMA Style
Sherifa Ahmed Hamed. Sleep Related Conditions with Myasthenia Gravis: Evidence, Causes and Implications. Sci J Public Health. 2015;4(2-1):6-16. doi: 10.11648/j.sjph.s.2016040201.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjph.s.2016040201.12,
author = {Sherifa Ahmed Hamed},
title = {Sleep Related Conditions with Myasthenia Gravis: Evidence, Causes and Implications},
journal = {Science Journal of Public Health},
volume = {4},
number = {2-1},
pages = {6-16},
doi = {10.11648/j.sjph.s.2016040201.12},
url = {https://doi.org/10.11648/j.sjph.s.2016040201.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjph.s.2016040201.12},
abstract = {Myasthenia gravis (MG) is an autoimmune disease caused mainly by antibodies against skeletal muscle nicotinic acetylcholine receptors (nAChRs) at the postsynaptic membrane resulting in depletion of acetylcholine at the neuromuscular junction (NMJ). Muscle fatigue is the cardinal symptom of MG. Respiratory muscle weakness and breathing problems are manifestations of MG even in mild stages of the disease resulting in significant morbidity and mortality. Also sleep related conditions are among the manifestations of MG which include sleep disordered breathing (SDB) [i.e. central (CSA) and obstructive (OSA) sleep apneas, hypoventilation or hypoxemic syndromes], reduced sleep efficiency and quality, increased number of nocturnal awakenings, excessive daytime sleepiness, reduced rapid eye movement sleep and altered sleep perception and dreaming. On the other hand, sleep abnormalities may result in lack of concentration, cognitive impairments and mood disturbances as depression and anxiety. Central and peripheral mechanisms have been suggested for the association between MG and central nervous system manifestations and sleep abnormalities. Neurologists and sleep medicine professionals should be aware of the associations between OSA/CSA, hypoventilation and other sleep related conditions with MG and consider systematic investigations including polysomnography and ventilatory support. This will reduce morbidity and mortality and improve quality of lives of patients with MG.},
year = {2015}
}
TY - JOUR T1 - Sleep Related Conditions with Myasthenia Gravis: Evidence, Causes and Implications AU - Sherifa Ahmed Hamed Y1 - 2015/09/08 PY - 2015 N1 - https://doi.org/10.11648/j.sjph.s.2016040201.12 DO - 10.11648/j.sjph.s.2016040201.12 T2 - Science Journal of Public Health JF - Science Journal of Public Health JO - Science Journal of Public Health SP - 6 EP - 16 PB - Science Publishing Group SN - 2328-7950 UR - https://doi.org/10.11648/j.sjph.s.2016040201.12 AB - Myasthenia gravis (MG) is an autoimmune disease caused mainly by antibodies against skeletal muscle nicotinic acetylcholine receptors (nAChRs) at the postsynaptic membrane resulting in depletion of acetylcholine at the neuromuscular junction (NMJ). Muscle fatigue is the cardinal symptom of MG. Respiratory muscle weakness and breathing problems are manifestations of MG even in mild stages of the disease resulting in significant morbidity and mortality. Also sleep related conditions are among the manifestations of MG which include sleep disordered breathing (SDB) [i.e. central (CSA) and obstructive (OSA) sleep apneas, hypoventilation or hypoxemic syndromes], reduced sleep efficiency and quality, increased number of nocturnal awakenings, excessive daytime sleepiness, reduced rapid eye movement sleep and altered sleep perception and dreaming. On the other hand, sleep abnormalities may result in lack of concentration, cognitive impairments and mood disturbances as depression and anxiety. Central and peripheral mechanisms have been suggested for the association between MG and central nervous system manifestations and sleep abnormalities. Neurologists and sleep medicine professionals should be aware of the associations between OSA/CSA, hypoventilation and other sleep related conditions with MG and consider systematic investigations including polysomnography and ventilatory support. This will reduce morbidity and mortality and improve quality of lives of patients with MG. VL - 4 IS - 2-1 ER -
Email: